Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors
Open Access
- 6 September 2022
- journal article
- research article
- Published by Ivyspring International Publisher in Theranostics
- Vol. 12 (15) , 6437-6445
Abstract
Rationale: This study aimed to assess the safety, efficacy, and survival of 177Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors (NETs).Keywords
This publication has 36 references indexed in Scilit:
- 177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Predictors of Long-Term Outcome in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with 177Lu-OctreotateJournal of Nuclear Medicine, 2014
- Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Long-Term Hematotoxicity After Peptide Receptor Radionuclide Therapy with 177Lu-OctreotateJournal of Nuclear Medicine, 2013
- Individualized Dosimetry of Kidney and Bone Marrow in Patients Undergoing 177Lu-DOTA-Octreotate TreatmentJournal of Nuclear Medicine, 2012
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid TumorsJournal of Nuclear Medicine, 2009
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United StatesJournal of Clinical Oncology, 2008
- Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and SurvivalJournal of Clinical Oncology, 2008
- LOCALISATION OF ENDOCRINE-RELATED TUMOURS WITH RADIOIODINATED ANALOGUE OF SOMATOSTATINThe Lancet, 1989
- CLINICAL STUDIES OF THE BLOOD VOLUME. I. CLINICAL APPLICATION OF A METHOD EMPLOYING THE AZO DYE “EVANS BLUE” AND THE SPECTROPHOTOMETERJournal of Clinical Investigation, 1937